The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rumyantsev N.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Research Center for Examination of Medical Products, Ministry of Health of Russia, Moscow, Russia

Kukes V.G.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Research Center for Examination of Medical Products, Ministry of Health of Russia, Moscow, Russia

Kazakov R.E.

Research Center for Examination of Medical Products, Ministry of Health of Russia, Moscow, Russia

Rumyantsev A.A.

N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy

Authors:

Rumyantsev N.A., Kukes V.G., Kazakov R.E., Rumyantsev A.A., Sychev D.A.

More about the authors

Journal: Therapeutic Archive. 2017;89(1): 82‑87

DOI: 10.17116/terarkh201789182-87

Read: 2737 times

Download PDF (RU)
Contact the author
Table of contents

USE OF PHARMACOGENETIC TESTING TO PREVENT ADVERSE DRUG REACTIONS DURING STATIN THERAPY
USE OF PHARMACOGENETIC TESTING TO PREVENT ADVERSE DRUG REACTIONS DURING STATIN THERAPY

To cite this article:

Rumyantsev NA, Kukes VG, Kazakov RE, Rumyantsev AA, Sychev DA. Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy. Therapeutic Archive. 2017;89(1):82‑87. (In Russ.)
https://doi.org/10.17116/terarkh201789182-87

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Safety profile of pressurized intraperitoneal aero­sol chemotherapy in the treatment of ovarian cancer. P.A. Herzen Journal of Onco­logy. 2024;(5):25-30
Treatment of postoperative complications in cardiothoracic surgery: single-center 10-year expe­rience. Piro­gov Russian Journal of Surgery. 2024;(12-2):66-71
Cere­bral protection in transcatheter aortic valve implantation. Piro­gov Russian Journal of Surgery. 2024;(12-2):150-158
Pharmacogenetic testing for personalized statin prescription in Moscow. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):49-55
Capsular contracture after reco­nstructive plastic surgery for breast cancer. P.A. Herzen Journal of Onco­logy. 2024;(6):78-83
Short- and mid-term outcomes after posterolateral endo­scopic discectomy in patients with lumbosacral junction disc herniations. Piro­gov Russian Journal of Surgery. 2024;(12):52-59
Complications after Laser Treatment. Journal of Venous Diso­rders. 2024;(4):317-327
Instrumental and labo­ratory indi­cators in evaluating the effe­ctiveness of suba­ntral sinus lifting in severe bone atro­phy. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(1):48-55
Early complications after surgical treatment of spontaneous pneumothorax: risk factors analysis. Piro­gov Russian Journal of Surgery. 2025;(3):24-32
The role of early predictors in diagnosis of stapler suture and anastomotic failure in bariatric patients. Piro­gov Russian Journal of Surgery. 2025;(3):76-86
Abstract:

The number of patients receiving statins increases every year and due to the fact that they should take statins during their lives, the problem of their safety use comes to the forefront. The paper analyzes the safety of using the medications of this group and discusses the diagnosis of myopathies induced by statins and the occurrence of immune-mediated statin myopathies. It considers a personalized approach to prescribing statins, analyzes Russian and foreign experience in using pharmacogenetics to reduce the risk of myopathies, publishes the results of the authors’ experience in clinically introducing pharmacogenetic testing at hospitals, and analyzes the long-term results of determining the polymorphism of the SLCO1B1 gene for the prediction of the risk of adverse events when using statins and estimating patient compliance to prescribed treatment.

Keywords:

statins
SLCO1B1
pharmacogenetics
myopathy
compliance
adverse drug reactions
complications

Authors:

Rumyantsev N.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Research Center for Examination of Medical Products, Ministry of Health of Russia, Moscow, Russia

Kukes V.G.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Research Center for Examination of Medical Products, Ministry of Health of Russia, Moscow, Russia

Kazakov R.E.

Research Center for Examination of Medical Products, Ministry of Health of Russia, Moscow, Russia

Rumyantsev A.A.

N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Close metadata

References:

  1. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-reactive protein be used to target statin therapy in primary prevention? The American journal of cardiology. 2006;97(2):33-41. doi:10.1016/j.amjcard.2005.11.014
  2. Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein New England Journal of Medicine. 2008;359(21)2195. doi:10.1016/j.jvs.2008.12.037
  3. Panza GA et al. Changes in muscle strength in individuals with statin-induced myopathy: A summary of 3 investigations. Journal of clinical lipidology. 2015;9(3):351-356. doi:10.1016/j.jacl.2015.01.004
  4. Mallinson JE et al. Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression. The Journal of physiology. 2015;593(5):1239-1257. doi:10.1113/jphysiol.2014.285577
  5. Parker BA et al. The effect of statins on skeletal muscle function. Circulation. 2012;1:96-103. doi:10.1161/circulationaha
  6. Klein M, Mann H, Plestilova L, et al. Increasing incidence of immunemediated necrotizing myopathy: single-centre experience. Rheumatology. 2015;54(11):2010-2014. doi:10.1093/rheumatology/kev229
  7. Mammen AL, Chung T, Christopher Stine L, et al. Autoantibodies against 3hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheumatology. 2011;63(3):713-721. doi:10.1002/art.30156
  8. Loganathan P, Oddis CV, Aggarwal R. Immune-mediated statin myopathy Expert review of clinical immunology. 2016;12(1):33-38. doi:10.1586/1744666x.2016.1103181
  9. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscular Disorders NMD. 2007;17(2):194-200. doi:10.1016/j.nmd.2006.10.007
  10. Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185-190. doi:10.1002/mus.21486
  11. Littarru GP, Langsjoen P. Coenzyme Q 10 and statins: biochemical and clinical implications Mitochondrion. 2007;7:168-174. doi:10.1016/j.mito.2007.03.002
  12. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review Journal of the American College of Cardiology. 2007; 49(23):2231-2237. doi:10.1016/j.jacc.2007.02.049
  13. Caso G et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. The American journal of cardiology. 2007;99(10):1409-1412. doi:10.1016/j.amjcard.2006.12.063
  14. Linde R et al. The role of vitamin D and SLCO1B1 gene polymorphism in statin-associated myalgias. Dermato-endocrinology. 2010;2(2):77-84. doi:10.4161/derm.2.2.13509
  15. Metabolizm lekarstvennykh sredstv: nauchnye osnovy personalizirovannoi meditsiny. Pod red Kukesa V. M.: GEOTAR-Media, 2008; ISBN: 9785970407295 (In Russ.)
  16. Carr DF, O'Meara H, Jorgensen AL et al. SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. Clinical Pharmacology & Therapeutics. 2013;94(6):695-701. doi:10.1038/clpt.2013.1611
  17. Sychev D. Rekomendatsii po primeneniyu farmakogeneticheskogo testirovaniya v klinicheskoi praktike Kachestvennaya klinicheskaya praktika. 2011;1:3-10. (In Russ.)
  18. Shuev G, Sychev D, Grachev A. Gene polymorphism of SLCO1B1, associated with the development of statin-induced myopathy, leves of vitamin d in russian patients with hyperlipidemia G. Kreativnaya kardiologiya. 2015;4:40-45. doi:10.15275/kreatkard.2015.04.05
  19. Voskoboinikov A i dr. Farmakogeneticheskoe testirovanie po allel'nomu variantu SLCO1B1* 5: znachenie dlya personalizatsii dozirovaniya statinov u patsientov s giperlipidemiyami. Byulleten' meditsinskikh Internet-konferentsii. 2013;3(6):975. ISSN 2224-6150
  20. Sirotkina A, Khokhlov A, Mogutova I. Rasprostranennost' polimorfnogo markera gena SLCO1B1 u patsientov s giperlipidemiei i nekotorykh polimorfnykh variantov genov u bol'nykh s arterial'noi gipertenziei. Nauka i sovremennost'. 2013;24:90-96. (In Russ.)
  21. Petrov V, Smuseva O, Solovkina Yu. Integrated assessment of statin-associated muscle damage predictors in patients with ischemic heart disease. Rational Pharmacotherapy in Cardiology. 2013;9(3):247-250. (In Russ.) doi:10.20996/1819-6446-2013-9-3-247-250
  22. Solodun M, Yakushin S. Aspects of lipid-lowering therapy with atorvastatin in patients with myocardial infarction from the perspective of personalized medicine. Pharmacotherapy in Cardiology. 2015;1:31-35. (In Russ.) doi:10.20996/1819-6446-2015-11-1-31-35
  23. Drapkina O.M., Chernova E.M., Myopathy as a side effect of statin therapy: mechanisms of development and prospects for treatment. Pharmacotherapy in Cardiology. 2015;21:96-101. (In Russ.) doi:10.20996/1819-6446-2015-11-1-96-101
  24. Postmus I et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature communications. 2014;5. doi:10.1038/ncomms6068
  25. Leusink M et al. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016;17(2):163-180. doi:10.2217/pgs.15.158
  26. Li JH et al. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. Journal of personalized medicine. 2014;4(2):147-162. doi:10.3390/jpm4020147
  27. Ramsey LB et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clinical Pharmacology & Therapeutics. 2014;96(4):423-428. doi:10.1038/clpt.2014.125
  28. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case—control studies. Medicine. 2015;94(37). doi:10.1097/md.0000000000001268
  29. Niemi Mikko. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics. 2006;16(12):873-879. doi:10.1097/01
  30. Tornio A et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenetics and genomics. 2015;25(8):382-387. doi:10.1111/j.1365-2125.2011.04139.x
  31. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin. Clinical Pharmacology & Therapeutics. 2007;82:726-733. doi:10.1038/sj.clpt.6100220
  32. Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy — Part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010;44:241-251. doi:10.1177/1538574410362922
  33. Davignon J. Pleiotropic effects of pitavastatin. British journal of clinical pharmacology. 2012;73(4):518-535.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.